Colon Cancer
Roche says phase III trial in metastatic colorectal cancer meets primary endpoints
Published in Clinical Oncology Week, August 28th, 2006
Results of the study showed the following:
1) The chemotherapy combination Xeloda plus oxaliplatin, called Xelox, is as effective in terms of progression-free survival - a measure of the time patients live without their disease progressing - as infused 5-fluorouracil/leucovorin plus oxaliplatin, called Folfox;
2) The addition of Avastin to chemotherapy (Folfox and Xelox) significantly improved progression-free survival compared to chemotherapy alone.
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
More Articles from Clinical Oncology Week
- Colorectal Cancer
Colorectal cancer patients' poor survival predicted by presence of systemic inflammatory response - Head & Neck Cancer
Mucositis and dermatitis in head and neck cancer patients improved with zinc supplementation - Merkel Cell Cancer
Merkel cell carcinoma evaluated and managed by sentinel lymph node biopsy - Prostate Cancer
Early or adjuvant therapy might not benefit prostate cancer patients at low risk for recurrence - Acoustic Neuromas
House Clinic offers Gamma Knife technology as treatment for acoustic neuromas - Acute Myeloid Leukemia
Acute myeloid leukemia survival improved with high-dose cytosine arabinoside - More from this issue of Clinical Oncology Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
